RECORD // Company

AbCellera Biologics Inc.

Built 2026-11-21T11:44:39Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • AbCellera Biologics Inc. · Ctgov · same registered legal name as 'AbCellera Biologics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001703057-26-000059

ItemValuePeriodFormFiledAccessionReport
Revenue$10,639,0003 months ended 2026-09-3010-Q2026-11-090001703057-26-0000592026-11-21 11:44 UTCReport an error
Net income (loss)$-40,758,0003 months ended 2026-09-3010-Q2026-11-090001703057-26-0000592026-11-21 11:44 UTCReport an error
Cash and cash equivalents$163,800,000at 2026-09-3010-Q2026-11-090001703057-26-0000592026-11-21 11:44 UTCReport an error
Contract liabilities (total)$83,088,000at 2026-09-3010-Q2026-11-090001703057-26-0000592026-11-21 11:44 UTCReport an error
Contract liabilities, current$35,038,000at 2026-09-3010-Q2026-11-090001703057-26-0000592026-11-21 11:44 UTCReport an error
Contract liabilities, noncurrent$48,050,000at 2026-09-3010-Q2026-11-090001703057-26-0000592026-11-21 11:44 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001703057
Ticker
ABCL
CUSIP
00288U106
Record ID
sx:sec:0001703057

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 11:44 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 11:44 UTCReport an error
State of incorporationA12026-11-16SEC EDGAR company profile2026-11-21 11:44 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 11:44 UTCReport an error
Business address150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G62026-11-16SEC EDGAR company profile2026-11-21 11:44 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 11:44 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$75,128,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:44 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-146,412,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:44 UTCReport an error
Total assets (at 2025-12-31)$1,356,950,0002025-12-3110-K, XBRL Assets2026-11-21 11:44 UTCReport an error
Stockholders' equity (at 2025-12-31)$966,904,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:44 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$128,513,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:44 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-131,295,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:44 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$42,772,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:44 UTCReport an error
Operating lease liabilities (at 2025-12-31)$143,218,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:44 UTCReport an error
Form D total offering amount (D filed 2020-05-27)$74,500,2352020-05-27D2026-11-21 11:44 UTCReport an error
Form D total amount sold (D filed 2020-05-27)$74,500,2352020-05-27D2026-11-21 11:44 UTCReport an error
Form D industry groupBiotechnology2020-05-27D2026-11-21 11:44 UTCReport an error
Form D revenue rangeDecline to Disclose2020-05-27D2026-11-21 11:44 UTCReport an error
Form D date of first sale2020-03-232020-05-27D2026-11-21 11:44 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.2026-11-09SEC EDGAR 8-K 0001703057-26-000058 (text as filed, excerpt)2026-11-21 11:44 UTCReport an error
8-K Item 7.01, Regulation FD (filed 2026-11-09)In connection with its earnings call on November 9, 2026, to discuss its results for the quarter ended September 30, 2026, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as…2026-11-09SEC EDGAR 8-K 0001703057-26-000058 (text as filed, excerpt)2026-11-21 11:44 UTCReport an error
8-K Item 7.01, Regulation FD (filed 2026-08-10)On August 10, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In connection with announcing the top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, the Company will hold an investor conference call and webcast at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) today. The webcast and accompanying investor presentation will be accessible on the “Investors” section of the company…2026-08-10SEC EDGAR 8-K 0001703057-26-000053 (text as filed, excerpt)2026-11-21 11:44 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-07)On August 7, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day.2026-08-07SEC EDGAR 8-K 0001703057-26-000049 (text as filed, excerpt)2026-11-21 11:44 UTCReport an error
Largest institutional holder #1 (13F as filed): BAKER BROS. ADVISORS LP$259,145,2832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #2 (13F as filed): Capital World Investors$106,668,5402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #3 (13F as filed): TWO SIGMA INVESTMENTS, LP$81,933,8332026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #4 (13F as filed): TD Waterhouse Canada Inc.$72,623,8732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #5 (13F as filed): BANK OF AMERICA CORP /DE/$48,211,0812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #6 (13F as filed): UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC$33,890,0672026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #7 (13F as filed): ArrowMark Colorado Holdings LLC$32,224,9962026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #8 (13F as filed): BlackRock, Inc.$29,871,6762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #9 (13F as filed): Driehaus Capital Management LLC$22,488,1232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error
Largest institutional holder #10 (13F as filed): TUDOR INVESTMENT CORP ET AL$16,196,0492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:44 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.